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ABSTRACT
Objective: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders
(NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to
improve rituximab monitoring and redosing.
Methods: Multicenter retrospective study of 16 children with NMO/NMOSD receiving$2 rituximab
courses. According to CD19 counts, events during rituximab were categorized as “repopulation,”
“depletion,” or “depletion failure” relapses (repopulation threshold CD19 $10 3 106 cells/L).
Results: The 16 patients (14 girls; mean age 9.6 years, range 1.8–15.3) had a mean of 6.1 events
(range 1–11) during a mean follow-up of 6.1 years (range 1.6–13.6) and received a total of 76
rituximab courses (mean 4.7, range 2–9) in 42.6-year cohort treatment. Before rituximab, 62.5%
had received azathioprine, mycophenolate mofetil, or cyclophosphamide. Mean time from rituximab
to last documented B cell depletion and first repopulation was 4.5 and 6.8 months, respectively,
with large interpatient variability. Earliest repopulations occurred with the lowest doses. Significant
reduction between pre- and post-rituximab annualized relapse rate (ARR) was observed (p5 0.003).
During rituximab, 6 patientswere relapse-free, although21 relapses occurred in 10 patients, includ-
ing 13 “repopulation,” 3 “depletion,” and 4 “depletion failure” relapses. Of the 13 “repopulation”
relapses, 4 had CD19 10–50 3 106 cells/L, 10 had inadequate monitoring (#1 CD19 in the 4
months before relapses), and 5 had delayed redosing after repopulation detection.
Conclusion: Rituximab is effective in relapse prevention, but B cell repopulation creates a risk of
relapse. Redosing before B cell repopulation could reduce the relapse risk further.
Classification of evidence: This study provides Class IV evidence that rituximab significantly reduces
ARR in pediatricNMO/NMOSD. This study also demonstrates a relationship betweenBcell repopulation
and relapses. Neurol Neuroimmunol Neuroinflamm 2016;3:e188; doi: 10.1212/NXI.0000000000000188
GLOSSARY
AQP45 aquaporin-4; ARR5 annualized relapse rate; EDSS 5 Expanded Disability Status Scale; IVIg 5 IV immunoglobulin;
MS 5 multiple sclerosis; MOG 5 myelin oligodendrocyte glycoprotein; NMO 5 neuromyelitis optica; NMOSD 5 NMO spec-
trum disorders; ON 5 optic neuritis; TM 5 transverse myelitis.
Neuromyelitis optica (NMO) is an autoimmune inflammatory demyelinating disease of the
CNS.1 Although previously considered a multiple sclerosis (MS) variant, IgG autoantibody
targeting aquaporin-4 (AQP4) channel (NMO-IgG) has clearly demonstrated that NMO is a
separate entity.2 NMO lesions are characterized by humoral inflammatory response and astro-
cytic cell death with AQP4 loss, followed by inflammatory demyelination and axonal damage.3
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The course of NMO is characterized by a
high relapse rate with accumulation of
neurologic disability, potentially causing
permanent blindness and paralysis. There-
fore, relapse prevention is crucial. Differenti-
ation from MS is important because some
MS therapies fail to control or may aggravate
NMO.4–6 Even though the optimal thera-
peutic regimen has not been established,
acute NMO attacks are mainly treated
with corticosteroids, plasma exchange, and
IV immunoglobulin (IVIg); azathioprine,
methotrexate, mycophenolate mofetil, ritux-
imab, mitoxantrone, cyclophosphamide, and
tocilizumab have been used to prevent
relapses.7
Rituximab is an anti-CD20 chimeric
monoclonal antibody that depletes B cells
that is used in severe autoimmune and
inflammatory CNS disorders despite the risk
of infections, as recently demonstrated in a
large pediatric study.8 One prospective and
3 retrospective adult NMO studies demon-
strated reduced annualized relapse rate
(ARR) and significantly improved Expanded
Disability Status Scale (EDSS) score with rit-
uximab.9–12 Pediatric data are more limited
and retrospective.13–16 No study specifically
addresses optimal rituximab monitoring and
redosing to prevent relapses and reduce dis-
ability. To clarify these aspects, we retrospec-
tively studied 16 children with NMO who
received $2 rituximab courses in order to
establish rituximab efficacy, the time from
rituximab to B cell repopulation, and the
relationship between B cell repopulation
and relapses.
METHODS Patients. We identified 16 patients with NMO
who received $2 rituximab courses (,18 years at first dose)
from 9 international pediatric neuroimmunology centers.
NMO was defined according to the revised Wingerchuk cri-
teria for NMO17 and NMO spectrum disorders (NMOSD).18
In 13 of 16 patients, diagnosis of definite NMO was met based
on the presence of both optic neuritis (ON) and transverse
myelitis (TM).19 The remaining 3 children had NMOSD (1
had a single attack of isolated TM, 1 had an attack of TM and
brainstem manifestations, and 1 had recurrent ON), and these
patients were all NMO-IgG positive. Regarding serologic
status, 15 of 16 patients were positive for NMO-IgG or
AQP4 antibodies: 12 were tested and positive for NMO-
IgG using immunofluorescence, and 3 were tested and
positive for both NMO-IgG (using immunofluorescence)
and anti-AQP4 antibodies (using cell-based assay). One
patient was negative for NMO-IgG but positive for anti–
myelin oligodendrocyte glycoprotein (MOG) antibodies
using cell-based assay (not tested for anti-AQP4 antibodies)
(patient 7).
Data collection. Data were retrospectively collected by the
main investigator (R.C.D.) through telephone interviews to
the physicians using a structured questionnaire created for this
study. Information recorded included demographics, clinical
characteristics of disease, immune therapies received besides
rituximab, rituximab regimen, CD19 count measurements,
and outcome. Data collection focused on the relationship
between rituximab administration (timing, dose, number of
courses, adverse reactions), CD19 counts, and relapses.
First-line immune therapy was defined as corticosteroids,
IVIg, and plasma exchange, whereas second-line immune
therapy included rituximab, cyclophosphamide, azathioprine,
and mycophenolate mofetil. Disease duration pre-rituximab
was defined as the time between onset (first event) and
initiation of rituximab treatment. Rituximab treatment
duration was defined as the time between rituximab
initiation and last follow-up (for patients with ongoing
rituximab) or the date of final CD19 repopulation (for
patients who stopped rituximab).
CD19 values and relationship to relapses. The threshold for
B cell repopulation was defined as CD19 count $10 3 106
cells/L, as previously proposed.16,20 In order to study the B cell
status during relapses, we used the CD19 count closest to the
clinical event (mean 4.6 days before or after the event, median 1,
range 0–22). We categorized a relapse as a “repopulation” relapse
when it was associated with B cell repopulation $10 3 106
cells/L, as a “depletion” relapse when it occurred despite B cell
depletion ,10 3 106 cells/L, or as a “depletion failure” relapse
when it occurred following a rituximab course failing to deplete B
cells despite conventional rituximab doses and adequate CD19
monitoring. In order to examine the timing of CD19 repopula-
tion, we used data only from rituximab courses with evidence of
both B cell depletion and subsequent repopulation (31 courses
from 13 patients).
Therapeutic efficacy. We used ARR as a clinical indicator of
therapeutic efficacy by comparing the ARR pre-rituximab and
during rituximab. ARR was calculated only when a time span of
$6 months was available.12 One relapse (patient 13) occurred 14
days after the first rituximab course and was considered to occur
before treatment effect because B cell depletion may take up to
1 month after rituximab administration.21 Pre- and post-rituximab
ARR were compared using the Wilcoxon 2-sample test (only
patients with both pre- and post-rituximab ARR were included).
EDSS score was calculated retrospectively to assess the neurologic
outcome at the last follow-up. We used Spearman correlation
coefficient (nonparametric) for correlating relapse number with
EDSS score at last follow-up.
Research questions and classification of evidence. Our pri-
mary research objectives were to determine the efficacy of ritux-
imab using ARR and to determine the relationship of relapses
to B cell repopulation. Given the retrospective nature of our study
and lack of a control group, our study represents Class IV
evidence.
Standard protocol approvals, registrations, and patient
consents. Patient data were acquired after local ethical approval
or using preexisting approved studies to collect deidentified clin-
ical data.
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RESULTS Demographics. Sixteen children (14 girls)
with NMO or NMOSD treated with $2 rituximab
courses were included in our study (mean age 9.6
years, median 10.9, range 1.8–15.3). The patient race
was white (n 5 8), black or African American (n 5
5), Native Pacific Islander (n 5 1), mixed white and
Native Pacific Islander (n 5 1), and mixed African,
Asian, and white (n 5 1).
Clinical presentation and disease course. Disease onset
was between 2000 and 2012. Ten patients had ON
and/or TM at onset (ON: n 5 4; TM: n 5 4; both
ON and TM: n 5 2). The other presentations were
brainstem disease only (n 5 3), TM and brainstem
disease (n 5 2), and ON and brainstem disease (n 5
1). The mean total duration of disease (time from
onset to last follow-up) was 6.1 years (median 5.1,
range 1.6–13.6). In the 16 children, 98 total events
occurred (mean 6.1, median 5, range 1–11), most of
which (71 of 98) were monosymptomatic attacks
(isolated ON: n 5 29; isolated TM: n 5 38;
isolated brainstem disease: n 5 4). The remaining
attacks were concurrent ON and TM (n 5 13); TM
and brainstem disease (n 5 9); ON, TM, and
brainstem disease (n 5 2); ON and brainstem
disease (n 5 1); or other (n 5 2). Figure 1 illustrates
the clinical course of the 16 patients (clinical events,
second-line immune therapies, and rituximab courses).
Immune therapies before rituximab. Before rituximab, all
patients received IV methylprednisolone followed by
oral prednisolone tapers; 8 patients received plasma
exchange and 8 received IVIg. Ten patients received
other second-line immune treatments before
rituximab (figure 1 and table 1): mycophenolate
mofetil (n 5 5; 2 of 5 also received azathioprine),
azathioprine (n 5 5; 2 of 5 also received
mycophenolate mofetil and 1 of 5 also received
cyclophosphamide), and cyclophosphamide (n 5 3;
1 of 3 also received azathioprine).
Figure 1 Clinical course of the 16 patients: Clinical events, second-line immune treatments, and rituximab courses
AZA 5 azathioprine; CYC 5 cyclophosphamide; MMF 5 mycophenolate mofetil; RTX 5 rituximab.
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Rituximab administration. A total of 76 rituximab
courses were administered in the 16 patients (mean
4.7, median 4.5, range 2–9) (figure 1). The mean
time between the first infusion of the first and last
rituximab courses was 29.8 months (median 23.5,
range 5.7–93). The protocols for administration (in
descending order of frequency) were as follows: 1,000
mg 3 2 infusions 2–4 weeks apart (n 5 31 courses),
375 mg/m2 3 4 weekly infusions (n 5 19 courses),
375 mg/m2 3 1 infusion (n 5 10 courses), 375
mg/m2 3 2 infusions 2 weeks apart (n 5 9 courses),
750 mg/m2 3 2 infusions 2 weeks apart (n 5 5
courses), and 500 mg/m2 3 2 infusions 2 weeks apart
(n 5 2 courses). Rituximab was redosed at a mean of
7.9 months (median 7.6, range 2.2–28.3). In some
patients it was redosed after a relapse, in others after
detection of B cell repopulation, and in a minority at
regular intervals regardless of B cell status. At last avail-
able follow-up, rituximab was ongoing in 13 patients.
Rituximab was discontinued in the 3 remaining
patients because of difficulty coming to the hospital
(patient 1), treatment failure (patient 2), and relapse
freedom for $2 years (patient 10).
Infusion reactions and adverse events. Data on infusion
reactions to rituximab and adverse events were
available in 14 of 16 patients. Infusion reactions
occurred in 6 of 14 children (dyspnea: n 5 2; rash:
n 5 2; chest pain: n 5 1; lightheadedness: n 5 1;
tingling and stinging sensation in mouth and throat:
n 5 1). Other adverse reactions occurred in 3 of 14
children, including infections in 2 (skin infection: n 5
1; mastoiditis: n 5 1) and immunoglobulin deficiency
without infectious complications in 1 (this patient
received 4 rituximab courses of 750 mg/m2 3 2).
Rituximab efficacy. Six patients were relapse-free
during rituximab treatment (patients 9, 10, 11, 13,
14, and 15) (table 2; figure 1). In these 6 relapse-
free patients, the rate of use of other immune
therapies during rituximab (corticosteroids: n 5 4;
IVIg: n 5 2; plasma exchange: n 5 0; second-line
immune therapies: n 5 0) was similar to the rate in
the other 10 patients (corticosteroids: n 5 9; IVIg:
n 5 4; plasma exchange: n 5 4; mycophenolate
mofetil 1 cyclophosphamide: n 5 1; azathioprine:
n 5 1). In the 10 relapsing patients, a total of 21
events occurred during rituximab treatment (mean
2.1, median 1.5, range 1–5) (table 2). Relapses
occurred a mean of 9.1 months (median 8.1, range
1.2–27.8) after the last rituximab course (figure 2A).
There was a statistically significant reduction between
Table 1 First-line and second-line immune treatments administered before rituximab
Patient Sex
Age at disease
onset, yr
First-line immune treatments before RTX
Second-line immune
treatments before RTX
Age at RTX
initiation, yrIVMP OP PE IVIg MMF AZA CYC
1 F 7.25 1 (5 courses) 1 2 2 2 1 2 12.92
2 M 1.83 1 (5 courses) 1 1 (1 cycle) 1 (1 course) 2 2 1 13.33
3 F 15.33 1 (2 courses) 1 1 (1 cycle) 2 2 2 2 15.92
4 F 9.58 1 (2 courses) 1 2 1 (2 courses) 2 2 2 10.25
5 F 8.08 1 (1 course) 1 2 1 (1 course) 2 2 2 8.17
6 F 10.83 1 (8 courses) 1 2 2 2 1 1 14.58
7 F 11 1 (1 course) 1 2 1 (2 courses) 2 2 2 11.25
8 F 7.75 1 (8 courses) 1 1 (3 cycles) 2 1 1 2 14.58
9 F 3.92 1 (6 courses) 1 2 1 (1 course) 1 1 2 13.92
10 F 12.42 1 (1 course) 1 2 2 2 2 2 12.67
11 F 11.75 1 (2 courses) 1 1 (1 cycle) 1 (1 course) 1 2 2 12.58
12 F 14.08 1 (2 courses) 1 1 (1 cycle) 2 1 2 2 15.33
13 M 11.17 1 (3 courses) 1 1 (1 cycle) 1 (8 courses) 1 2 2 11.75
14 F 5.67 1 (7 courses) 1 2 1 (1 course) 2 1 2 11.17
15 F 11.33 1 (3 courses) 1 1 (15 cycles) 2 2 2 2 13.67
16 F 11.25 1 (4 courses) 1 1 (3 cycles) 2 2 2 1 14
Abbreviations: AZA 5 azathioprine; CYC 5 cyclophosphamide; IVIg 5 IV immunoglobulin; IVMP 5 IV methylprednisolone; MMF 5 mycophenolate mofetil;
OP 5 oral prednisolone; PE 5 plasma exchange; RTX 5 rituximab.
When available, the number of treatment courses and cycles is provided in parentheses. Before rituximab, all patients received IV methylprednisolone (total
60 courses; mean 3.7 courses per patient, median 3, range 1–8) followed by oral prednisolone. Plasma exchange was administered in 8/16 patients (total
26 cycles; mean 3.2 cycles per patient, median 1, range 1–15; in data available, there were mean 5.2 exchanges per cycle, median 5, range 1–10). IVIg was
administered in 8/16 patients (total 17 courses; mean 2.1 courses per patient, median 1, range 1–8).
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pre- and post-rituximab ARR when first events were
included (p 5 0.003) or excluded (p 5 0.014) (table
2). There was also a significant reduction in the ARR
in the year after rituximab initiation compared to the
year before (p 5 0.002).
CD19 count monitoring and repopulation on rituximab.
During the total 42.6 years of cohort rituximab treat-
ment, a total of 196 CD19 counts were measured
(mean 12.2 per patient, median 9, range 1–36). All
patients had documented B cell depletion after at least
1 rituximab course. In the 31 rituximab courses (in
13 patients) with documented B cell depletion fol-
lowed by repopulation, the mean time from rituxi-
mab administration to the last demonstrated depleted
CD19 count was 4.5 months (median 5.1, range 0.9–
8.7), and the mean time to the first demonstrated
repopulated CD19 count was 6.8 months (median
6.7, range 2.7–12.2). The 2 shortest times to repo-
pulation occurred 2.7 and 2.9 months after rituximab
(375 mg/m2 3 1 and 375 mg/m2 3 2, respectively)
in 2 different patients. We observed notable interpa-
tient variability in the time to B cell repopulation and
some intrapatient variability (figure 2B). The mean
time to repopulation in the first rituximab courses
(mean 7.4 months, median 7.2, range 3.6–12.2;
calculated in 8 courses) was similar to that in subse-
quent courses (mean 6.7 months, median 6.8, range
2.7–11.2; calculated in 23 courses). Time to B cell
repopulation was faster in the younger patients (18
courses in 5 patients with adequate data; age range
8.2–11.7 years at rituximab initiation) than in the older
patients (12 courses in 7 patients; age range 13.3–15.9
years at rituximab initiation) (mean 5.9 vs 8.1 months,
median 5.6 vs 8.5 months). Where adequate data were
available (n 5 10 courses), once B cells repopulated
over the threshold of 10 3 106 cells/L, B cell counts
never redepleted spontaneously. In contrast, according
to available data (n 5 9 courses), only 22% of CD19
counts 1–93 106 cells/L were followed by repopulated
CD19 values $10 3 106 cells/L within 1 month.
CD19 count and relationship to relapses. The 21 relapses
that occurred in 10 children during rituximab treat-
ment are detailed in table e-1 at Neurology.org/nn
(adequate CD19 data in 20 of 21 relapses). Most of
the events (13 of 20) occurred with B cell
repopulation and are defined as “repopulation”
relapses. In these 13 “repopulation” relapses, the
mean CD19 value at relapse was 192.3 3 106 cells/
L (median 130, range 10–449), and in 4 of these 13
events the CD19 count was 10–50 3 106 cells/L
Table 2 Duration of disease, number of events, and ARR pre- and post-rituximab
Patient
Disease duration
pre-RTX, mo
Duration of RTX
treatment, mo
No. events
pre-RTX (including
first event)
No. events during
RTX treatment
ARR pre-RTX including
first event (excluding
first event)
ARR during
RTX
ARR in the
year before
RTX
ARR in the
year after
RTX
1 67.5 22 5 1 0.89 (0.71) 0.54 1 1
2 137 23 5 5 0.44 (0.35) 2.61 1 0
3 4 26 2 1 — 0.46 — 1
4 8 17.3 2 2 3.00 (1.50) 1.39 — 1
5 1.3 27.5 1 2 — 0.87 — 0
6 45 46 9 2 2.40 (2.13) 0.52 3 1
7 3.2 31 2 1 — 0.39 — 1
8 82.3 26 10 1 1.46 (1.31) 0.46 3 0
9 123.7 39.5 9 0 0.88 (0.78) 0 1 0
10 2.5 33.5 1 0 — 0 — 0
11 9.7 9.2 2 0 2.47 (1.24) 0 — 0
12 15 7 3 1 2.40 (1.60) 1.71 2 1
13 7.5 22.7 4 0 6.40 (4.80) 0 — 0
14 66 30 10 0 1.82 (1.64) 0 1 0
15 28 52.7 7 0 3.00 (2.57) 0 3 0
16 33 98 5 5 1.82 (1.45) 0.61 1 0
Mean 39.6 Mean 32 Mean 4.8 Mean 1.3 Mean 2.2 (1.5) Mean 0.6 Mean 1.7 Mean 0.4
Median 21.5 Median 26.7 Median 4.5 Median 1 Median 2.1 (1.5) Median 0.5 Median 1 Median 0
Range 1.3–137 Range 7–98 Range 1–10 Range 0–5 Range 0.4–6.4 (0.3–3.2) Range 0–2.6 Range 1–3 Range 0–1
Abbreviations: ARR 5 annualized relapse rate; RTX 5 rituximab.
There was a statistically significant reduction between pre- and post-rituximab ARR when first events were included (p 5 0.003) or excluded (p 5 0.014).
There was also a significant reduction in the ARR in the year before and after rituximab initiation (p 5 0.002).
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(10, 16, 37, and 40 3 106 cells/L). Of the 13
“repopulation” relapses, there was a lack of monitoring
(defined as#1 CD19 count in the 4 months preceding
the relapse) in 10, a delay in redosing (defined as
$10 days between detection of repopulation and
rituximab redosing) during which the relapse
occurred in 5, and there was no inadequate
monitoring or delayed redosing in 2.
The remaining 7 clinical events occurred in 2 pa-
tients: 3 relapses in patient 2 (rituximab 750 mg/m2 3
2 infusions 2 weeks apart) occurred despite B cell
depletion and were defined as “depletion” relapses,
whereas the 4 relapses in patient 16 (rituximab
1,000 mg3 2 infusions 4 weeks apart) occurred with
documented persistent nondepleted CD19 counts
(mean 6.2 CD19 counts/relapse, median 6, range
2–11) and were defined as “depletion failure” relap-
ses. Examples of relapse freedom after treatment and
of “repopulation,” “depletion,” and “depletion fail-
ure” relapses are presented in figures 3 and e-1.
Outcome. At a mean follow-up of 6.1 years from
disease onset (median 5.1 years, range 1.6–13.6),
mean EDSS score was 2.4 (median 2.5, range 0–
6.5), and no ongoing problems (EDSS 0) were
reported in 5 patients. There was a trend of worse
EDSS scores at follow-up in the patients who had
more relapses during the disease course, but this
was not statistically significant (r 5 0.49, p 5
0.051). The most common neurologic problem at
follow-up was reduced visual acuity, reported in 10
of 16 cases; in 6 of these 10 patients visual acuity was
severely reduced (worse eye with maximal visual
acuity corrected less than 20/200). Pyramidal signs
in the lower limbs were reported in 2 of 16 cases,
upper limb involvement in 0 of 16, and bowel or
bladder impairment in 1 of 16.
DISCUSSION We retrospectively studied 16 chil-
dren with NMO treated with $2 rituximab courses
with the aim of optimizing rituximab monitoring and
Figure 2 Time to relapse and time to B cell repopulation after rituximab
(A) Relapses during rituximab (RTX) treatment according to the time from last rituximab course (total 21 relapses in 10 pa-
tients). (B) Inter- and intraindividual variability in the time to B cell repopulation after rituximab in 9 patients. To assess the
variability in the intraindividual time to repopulation, these 9 patients were selected based on the availability of at least 2
rituximab courses with evidence of a repopulated CD19 count after demonstrated depletion and the fact that the same
dose regimen was administered (rituximab regimen specified for each patient next to the bar). The horizontal bars represent
the range of intraindividual variability in the time to repopulation, and the dots represent the actual measurements. There is
significant variability between patients, although the intrapatient variability appears to be less.
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Figure 3 Summary figure exemplifying 4 different types of response to rituximab treatment observed in our patients
Relapse freedom with rituximab (RTX) (A, B), occurrence of relapses with a repopulated B cell count (“repopulation” relapses; C, D), occurrence of relapses with a
depleted B cell count (“depletion” relapses; E), occurrence of relapses in association with failure to reach B cell depletion (“depletion failure” relapses; F). (A) Relapse
freedom (no relapses during rituximab): rituximab redosing after B cell repopulation (patient 14). (B) Relapse freedom (no relapses during rituximab): rituximab
redosing before B cell repopulation (patient 10). (C) “Repopulation” relapses (relapses with B cell repopulation): repopulation was detected only at the time of the
relapse (third and fourth relapses); subsequent rituximab courses were administered after the relapse (second and third rituximab courses) (patient 4). (D) “Repo-
pulation” relapses (relapses with B cell repopulation): repopulation was noticed at CD19 count monitoring and rituximab was administered, but clinical relapse
occurred a fewdays after rituximab, before depletionwas achieved (second and third relapses) (patient 5). (E) “Depletion” relapses (relapses despite B cell depletion in
Continued
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redosing to prevent relapses. This represents the larg-
est reported therapeutic study of pediatric NMO.
Confirming published literature, there was a
female predominance in our cohort, and most of
the clinical events were monosymptomatic TM,
ON, and brainstem events. Our patients had a high
relapse rate and a long disease course before rituximab
initiation. Fifteen of the 16 patients were NMO-IgG
positive, although the single MOG-IgG-positive
patient had 2 events in the 3 months preceding ritux-
imab initiation and 1 relapse during rituximab,
suggesting a highly relapsing disease. Although
long-term data regarding MOG-IgG-associated dis-
ease are lacking, early reports suggest that MOG-
IgG-associated NMOSD is more reversible and less
severe and carries less risk of permanent disability
compared to NMO-IgG-associated NMOSD.19,22
All patients received immunosuppressive therapies
before rituximab: all received IV methylprednisolone
and oral steroids, half received IVIg, half received
plasma exchange, and 62.5% were given other
second-line immune therapies before rituximab. Rit-
uximab was generally initiated after $2 events,
although it was started after the first event in 3 cases.
Overall, our cohort likely represents a more severe
end of the pediatric NMO spectrum.
In our cohort, the protocols of rituximab induc-
tion, redosing, and monitoring were heterogeneous,
reflecting the multicenter nature of our cohort and
the lack of guidelines and consensus opinion. Ritux-
imab was redosed at a mean of 7.9 months, although
with considerable variability (range 2.2–28.3
months). Redosing occurred for different reasons,
including occurrence of relapses, detection of B cell
repopulation, or, more rarely, planned redosing (fig-
ures 3 and e-1).
Rituximab treatment was relatively well tolerated
with no major complications in 42.6-year cohort treat-
ment. There was evidence of efficacy in our cohort; 6
of the patients were relapse-free during treatment
(figures 3, A and B and e-1). There was a significant
reduction in ARR using all measures, although it is
important to note that the ARR may decline during
the course of disease regardless of treatment.23 The use
of other immune therapies was similar in the 6 relapse-
free patients compared to the other patients, suggesting
that the lack of relapses was not due to other concom-
itant therapies administered with rituximab.
The clinical events during rituximab occurred a mean
of 9.1 months after the last rituximab course, although
the timing of relapses was very widely distributed.
We chose a CD19 count of 10 3 106 cells/L as a
threshold for B cell repopulation, as previously used,16,20
partly because absolute values (rather than percentages)
would allow adequate comparison across centers. The
observation that 4 of the 13 “repopulation” relapses
in our cohort occurred during early repopulation
(10–50 3 106 cells/L) confirms the clinical validity of
10 3 106 cells/L as a threshold. We also observed that
once B cells repopulated beyond 10 3 106 cells/L,
CD19 counts continued to rise and there was no spon-
taneous return to B cell redepletion.
We confirmed a relationship between B cell repo-
pulation and relapses. Most relapses occurred with
CD19 repopulation, and only 1 patient had relapses
with depleted CD19 counts, confirming that deple-
tion appears to be protective in most patients. In most
of the 13 “repopulation” relapses, CD19 monitoring
was inadequate and B cell repopulation went unno-
ticed until subsequent clinical relapse. In 5 of the
“repopulation” relapses, there was delayed rituximab
redosing after detection of B cell repopulation and
relapses occurred while waiting to admit the patient
for redosing. Furthermore, B cell depletion can take
up to 1 month after rituximab administration,21
allowing for a “window of vulnerability” for relapses
(as shown in figure 3D). The remaining 7 relapses
occurred in 2 patients, defined as “depletion” relapse
in one patient (figure 3E) and “depletion failure”
relapse in the other (figure 3F). Therefore, only 1 of
the 16 patients (patient 2) had relapses despite ade-
quate monitoring and documented B cell depletion
and can therefore be defined as having true rituximab
failure. The reason for the different response to ritux-
imab in these 2 patients with “depletion” and “deple-
tion failure” relapses is not clear, although some
investigators have suggested that B cell activating
factor of the tumor necrosis factor family may be
relevant.20,24–26 Some studies in adult patients have
shown a relationship of anti-AQP4 antibodies with
B cell status and clinical relapses,11,27,28 although
others have not found a convincing relationship.20
Unfortunately, longitudinal anti-AQP4 antibodies
were not available in our cohort.
In light of the above considerations on the rela-
tionship between B cell repopulation and relapses,
understanding the timing of repopulation after ritux-
imab is critical for preventing relapses. The mean
time for B cell repopulation in our cohort was
between 4.5 (mean time of last depletion) and 6.8
months (mean time of first repopulation) after the last
rituximab course. However, repopulation as early as
Figure 3 legend, continued:
the last 3 relapses) (patient 2). (F). “Depletion failure” relapses (relapses associated with failure to reach B cell depletion in the first, second, and third
rituximab courses). In this patient, B cell depletion was achieved in subsequent rituximab courses (total 9 courses; same rituximab regimen used in all the
courses, 1,000 mg 3 2). The figure shows only the first 5 courses; no relapses occurred subsequently.
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2.7 months post-rituximab and persistent B cell
depletion up to 8.7 months were observed, suggesting
large interpatient variability in CD19 count effects
(figure 2B), similar to other published data.29 In
contrast, the intrapatient variability appeared to be
smaller, implying a relative predictability of B cell re-
population in individuals, which will help monitoring.
We noted that the shortest time to repopulation
occurred with the lowest rituximab doses and the lon-
gest with the highest doses, as previously observed,29
although other variables likely play a role in B cell
repopulation. We also observed that younger patients
repopulated faster than older patients.
In our study, we observed that genuine treatment
failure with rituximab occurred in only 1 patient,
whereas relapses were otherwise attributable to the
challenges associated with monitoring and redosing.
We confirm that rituximab efficacy is associated with
CD19 depletion, and our data suggest that the detec-
tion of repopulation over 10 3 106 cells/L should
alert the clinician to the likely possibility of further
B cell rise and relapse risk. Considering the significant
variability observed in the time to B cell repopulation,
further efforts should be made to optimize rituximab
monitoring. A possible individualized strategy
to minimize relapses involves rigorous CD19 moni-
toring (i.e., monthly, especially after the third
month), particularly during first courses, and rapid
redosing on repopulation detection. Given the
latency of B cell depletion after rituximab infusion,
there is a risk of relapse during this repopulated
period, especially when there is delay in redosing.
In view of this, an alternative strategy involves
planned rituximab redosing at regular intervals,
before B cell repopulation occurs, as previously
described9,10,20 and shown in figure 3B, which may
reduce the relapse risk but will result in increased
therapy cost. As shown in figure 2B, there is signifi-
cant variability in B cell repopulation between pa-
tients, including early repopulation (3–6 months)
even for higher dose regimens (375 mg/m2 3 4 and
1,000 mg/m2 3 2). Therefore, planned redosing
would need to be at short intervals (3–4 months)
to minimize the chance of B cell repopulation.
The retrospective design, the lack of standardiza-
tion, and the relatively small number of patients are
the main limitations of our study. However, we have
confirmed rituximab efficacy, demonstrated chal-
lenges in monitoring, and provided data on B cell re-
population. This will improve redosing of rituximab
in children with NMO and other serious autoim-
mune disorders of the CNS.
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